EUDA Health Holdings Limited (EUDA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
EUDA Health Holdings Limited stock (EUDA) is currently trading at $11.47. EUDA Health Holdings Limited PE ratio is 0.92. EUDA Health Holdings Limited PS ratio (Price-to-Sales) is 0.13. Analyst consensus price target for EUDA is $55.00. WallStSmart rates EUDA as Sell.
- EUDA PE ratio analysis and historical PE chart
- EUDA PS ratio (Price-to-Sales) history and trend
- EUDA intrinsic value — DCF, Graham Number, EPV models
- EUDA stock price prediction 2025 2026 2027 2028 2029 2030
- EUDA fair value vs current price
- EUDA insider transactions and insider buying
- Is EUDA undervalued or overvalued?
- EUDA Health Holdings Limited financial analysis — revenue, earnings, cash flow
- EUDA Piotroski F-Score and Altman Z-Score
- EUDA analyst price target and Smart Rating
EUDA Health Holdings
📊 No data available
Try selecting a different time range
EUDA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · EUDA Health Holdings Limited (EUDA)
EUDA trades at a significant discount to its Graham intrinsic value of $2.72, offering a 68% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
EUDA Health Holdings Limited (EUDA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
EUDA Health Holdings Limited (EUDA) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Revenue surging 60.20% year-over-year
Supporting Valuation Data
EUDA Health Holdings Limited (EUDA) Areas to Watch (4)
Losing money on operations
Very low institutional interest at 0.09%
Micro-cap company with very limited liquidity and high volatility
Thin profit margins with limited profitability
EUDA Health Holdings Limited (EUDA) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (0.13) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 60.20%.
The Bear Case
The primary concerns are Operating Margin, Institutional Own., Market Cap. Profitability pressure is visible in Operating Margin at -37.00%, Profit Margin at 5.17%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -37.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 60.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EUDA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EUDA's Price-to-Sales ratio of 0.13x trades at a deep discount to its historical average of 32.41x (0th percentile). The current valuation is 100% below its historical high of 83.19x set in Oct 2022, and 3% above its historical low of 0.13x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~34.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for EUDA Health Holdings Limited (EUDA) · REAL ESTATE › REAL ESTATE SERVICES
The Big Picture
EUDA Health Holdings Limited is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 5M with 60% growth year-over-year. Profit margins are thin at 5.2%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 60% YoY, reaching 5M. This pace significantly outperforms most REAL ESTATE SERVICES peers.
Debt-to-equity ratio of -0.62 indicates a conservative balance sheet with 176,584 in cash.
Free cash flow is -619,323, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can EUDA Health Holdings Limited push profit margins above 15% as the business scales?
Growth sustainability: can EUDA Health Holdings Limited maintain 60%+ revenue growth, or will competition slow it down?
Debt management: total debt of 2M is significantly higher than cash (176,584). Monitor refinancing risk.
Sector dynamics: monitor REAL ESTATE SERVICES industry trends, competitive moves, and regulatory changes that could impact EUDA Health Holdings Limited.
Bottom Line
EUDA Health Holdings Limited is a high-conviction growth story with revenue accelerating at 60% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 5.2% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:36 AM
About EUDA Health Holdings Limited(EUDA)
NASDAQ
REAL ESTATE
REAL ESTATE SERVICES
USA
EUDA Health Holdings Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. Utilizing advanced technologies and a dynamic pipeline, the company aims to tackle critical challenges in supportive care and immune modulation. With a strong emphasis on research and development, EUDA is well-positioned to lead healthcare innovation, committed to improving patient outcomes and expanding access to vital medical therapies through its promising clinical programs.